These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 15683095)

  • 41. Antisaccadic effects of a dopamine agonist as add-on therapy in advanced Parkinson's patients.
    Crevits L; Versijpt J; Hanse M; De Ridder K
    Neuropsychobiology; 2000; 42(4):202-6. PubMed ID: 11096336
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A randomly assigned double-blind cross-over study examining the relative anti-parkinsonian tremor effects of pramipexole and pergolide.
    Navan P; Findley LJ; Undy MB; Pearce RK; Bain PG
    Eur J Neurol; 2005 Jan; 12(1):1-8. PubMed ID: 15613140
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pergolide monotherapy for Parkinson's disease.
    van der Worp B
    J Neurol; 1999 Oct; 246(10):983-4. PubMed ID: 10610397
    [No Abstract]   [Full Text] [Related]  

  • 44. Pergolide-induced ergotism.
    Morgan JC; Sethi KD
    Neurology; 2006 Jul; 67(1):104. PubMed ID: 16832086
    [No Abstract]   [Full Text] [Related]  

  • 45. Heart valve regurgitation, pergolide use, and parkinson disease: an observational study and meta-analysis.
    Corvol JC; Anzouan-Kacou JB; Fauveau E; Bonnet AM; Lebrun-Vignes B; Girault C; Agid Y; Lechat P; Isnard R; Lacomblez L
    Arch Neurol; 2007 Dec; 64(12):1721-6. PubMed ID: 18071034
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Valvular heart disease in pergolide-treated Parkinson's disease.
    Scozzafava J; Takahashi J; Johnston W; Puttagunta L; Martin WR
    Can J Neurol Sci; 2006 Feb; 33(1):111-3. PubMed ID: 16583734
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nocturnal activity with nighttime pergolide in Parkinson disease: a controlled study using actigraphy.
    Comella CL; Morrissey M; Janko K
    Neurology; 2005 Apr; 64(8):1450-1. PubMed ID: 15851743
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dopaminergic agonists in the treatment of Parkinson's disease.
    Goetz CG
    Neurology; 1990 Oct; 40(10 Suppl 3):suppl 50-4; discussion 54-7. PubMed ID: 1977104
    [No Abstract]   [Full Text] [Related]  

  • 49. Sleep attacks and Parkinson's disease treatment.
    Ferreira JJ; Galitzky M; Montastruc JL; Rascol O
    Lancet; 2000 Apr; 355(9212):1333-4. PubMed ID: 10776750
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Experience of pergolide in the treatment of Chinese parkinsonian patients with dose-related fluctuations.
    Shan DE; Yeh SI
    Zhonghua Yi Xue Za Zhi (Taipei); 1995 Nov; 56(5):312-8. PubMed ID: 8605645
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Normalization of voice in spasmodic dysphonia during transient global amnesia.
    Kishore A; Lang AE
    Mov Disord; 2005 Sep; 20(9):1228-9. PubMed ID: 15954130
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Effects of low-dose pergolide therapy on cardiac valves in patients with Parkinson's disease].
    Muraki M; Mikami T; Kitaguchi M; Sugawara T; Isonishi K; Kaneko S; Kashiwaba T; Moriwaka F; Yamada S; Onozuka H; Tsutsui H
    J Cardiol; 2005 Dec; 46(6):221-7. PubMed ID: 16389741
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Tactile hallucinations induced by trihexyphenidyl in a patient with Parkinson's disease].
    Funakawa I; Jinnai K
    Rinsho Shinkeigaku; 2005 Feb; 45(2):125-7. PubMed ID: 15782612
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [New trends in the treatment of Parkinson disease: current findings on neuroprotection and high dose dopamine agonist therapy].
    Psychiatr Prax; 1997 Nov; 24(6 Suppl Neue Wege):1-4. PubMed ID: 9431364
    [No Abstract]   [Full Text] [Related]  

  • 55. Painful dystonic spasms in Parkinson's disease.
    Ilson J; Fahn S; Côté L
    Adv Neurol; 1984; 40():395-8. PubMed ID: 6695618
    [No Abstract]   [Full Text] [Related]  

  • 56. Long-term efficacy of pergolide in patients with Parkinson's disease.
    Sage JI; Duvoisin RC
    Clin Neuropharmacol; 1986; 9(2):160-4. PubMed ID: 3708601
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Influences of dopaminergic treatment on motor cortex in Parkinson disease: a MRI/MRS study.
    Lucetti C; Del Dotto P; Gambaccini G; Ceravolo R; Logi C; Berti C; Rossi G; Bianchi MC; Tosetti M; Murri L; Bonuccelli U
    Mov Disord; 2007 Nov; 22(15):2170-5. PubMed ID: 17722082
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Constrictive pericarditis and pleuropulmonary fibrosis secondary to cabergoline treatment for Parkinson's disease.
    Townsend M; MacIver DH
    Heart; 2004 Aug; 90(8):e47. PubMed ID: 15253989
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Telogen effluvium associated with the dopamine agonist pramipexole in a 55-year-old woman with Parkinson's disease.
    Katz KA; Cotsarelis G; Gupta R; Seykora JT
    J Am Acad Dermatol; 2006 Nov; 55(5 Suppl):S103-4. PubMed ID: 17052518
    [No Abstract]   [Full Text] [Related]  

  • 60. [Pergolide use and heart valve fibrosis. Yearly control in patients with Parkinson disease who use pergolide].
    van Laar T; Berendse H; Bloem BR; Boon AJ; van Hilten JJ; Hovestadt A; de Koning-Tijssen MA; Nijssen PC; Weber WE
    Ned Tijdschr Geneeskd; 2009 Jan; 153(3):87-90. PubMed ID: 19235345
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.